House bill HR2542-119

Ways and Means Committee

To amend titles XVIII and XIX of the Social Security Act to provide that priority research drugs shall not be treated as line extensions of existing drugs for purposes of calculating manufacturer rebates under the Medicare and Medicaid programs, and for other purposes.

• Last activity on Apr 01, 2025

• Introduced Apr 01, 2025

• By Rep. Davis, Donald G. [D-NC-1]

Support this bill

IntroReferral

Apr. 01
2025

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

IntroReferral
Apr. 01 2025	Introduced in House Introduced in House